Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacobezoar: an evolving new entity

P E Stack1, E Thomas

  • 1Division of Gastroenterology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA.

Digestive Diseases (Basel, Switzerland)
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The molecular neuron-glia couple and epileptogenesis.

Advances in neurology·1999
Same author

Rabbit corneal and conjunctival permeability of the novel aldose reductase inhibitors: N-[[4-(benzoylamino)phenyl] sulphonyl]glycines and N-benzoyl-N-phenylglycines.

The Journal of pharmacy and pharmacology·1999
Same author

Colo-cholecystic fistula: an unusual complication of colonic diverticular disease.

The American journal of gastroenterology·1999
Same author

Clinical usefulness of biochemical resorption markers in osteoporosis.

Annals of clinical biochemistry·1999
Same author

Short-term physical risk factors for new episodes of low back pain. Prospective evidence from the South Manchester Back Pain Study.

Spine·1999
Same author

Oral etoposide for patients with advanced adenocarcinoma of the pancreas.

Investigational new drugs·1999

Pharmacobezoars, or medication bezoars, are rare gastrointestinal masses. Clinicians should consider them in patients with motility issues, as they can cause unique symptoms from drug release.

Area of Science:

  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Pharmacobezoars are unusual bezoars formed from medications.
  • They are often associated with gastrointestinal motility disorders or anatomical abnormalities.

Purpose of the Study:

  • To review the formation, contributing factors, and clinical presentation of pharmacobezoars.
  • To highlight the importance of considering pharmacobezoars in the differential diagnosis of gastrointestinal emptying problems.

Main Methods:

  • Literature review of reported cases and contributing factors for pharmacobezoar formation.
  • Analysis of medication properties and patient conditions predisposing to bezoar development.

Main Results:

  • Commonly implicated medications include aluminum hydroxide gel, enteric-coated aspirin, sucralfate, and psyllium.

Related Experiment Videos

  • Factors like bowel hypoactivity, dehydration, and use of anticholinergics/narcotics contribute to formation.
  • Unlike other bezoars, pharmacobezoars can cause additional symptoms due to active ingredient release.

    • Conclusions:

    • Altered gastrointestinal motility and anatomy are key factors in pharmacobezoar formation.
    • Specific drug properties (hygroscopic, insoluble vehicles) influence bezoar development.
    • Pharmacobezoars should be considered in patients presenting with unexplained gastrointestinal emptying issues.